Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 185 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Diffuse, Large B-Cell, Lymphoma Clear all
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma, Non Hodgkin Lymphoma (NHL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Interventions
12-Day Production of Car-T Cells, 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
ALL, AML, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, B Cell Lymphoma, Burkitt Lymphoma, CML, Chronic Myelogenous Leukemia, Cutaneous B-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hematologic Malignancy, Hodgkin Lymphoma, Leukemia, Lymphoma, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, T-cell Lymphoma
Interventions
1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 38 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 12:54 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Interventions
Anti-CD19 CAR-T cells
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 10, 2026, 8:52 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
B ALL, B-ALL, DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, Diffuse Large B-cell Lymphoma, Dlbcl-Ci, HGBL, HGBL, Nos
Interventions
131-I Apamistamab, CAR T-cell
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 18, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
CLL/SLL, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
LP-168
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
Inactivated Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 20, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel
Biological · Procedure · Drug + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
87
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 18, 2026, 5:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Diffuse Large B-cell Lymphoma
Interventions
Zanubrutinib
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Apr 29, 2026, 8:34 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Interventions
De-escalated Treatment, Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment
Other · Device
Lead sponsor
Hua-Jay J Cherng, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 16, 2026, 8:41 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced May 4, 2026, 4:40 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma
Interventions
Cyclophosphamide, Fludarabine, anti-CD19 CAR-T cells
Drug · Biological
Lead sponsor
C. Babis Andreadis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced May 20, 2026, 11:51 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Bladder Cancer, Carcinoma in Situ, Cervix Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Head and Neck Squamous Cell Carcinoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Metastatic Cancer, Skin Cancer, Triple Negative Breast Cancer, Tumor Recurrence, Tumor, Solid, Uveal Melanoma, Recurrent
Interventions
Cemiplimab, ONM-501
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced May 19, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma of Breast, Diffuse Large B Cell Lymphoma of Testis, Double Expressor DLBCL, HIV-associated Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Intravascular Large B-Cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma
Interventions
Cerebral Spinal Fluid ctDNA
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 18, 2026, 4:32 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Fludeoxyglucose F-18, Multigated Acquisition Scan, Polatuzumab Vedotin, Positron Emission Tomography, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine
Procedure · Drug · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Apr 29, 2026, 12:17 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, High-grade B-cell Lymphoma, Large B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Emapalumab, Fludarabine Phosphate
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 17, 2026, 1:03 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
Tazemetostat Pill
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced May 11, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Burkitt Lymphoma, CD20+ Lymphoblastic Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Grade III, Non-Hodgkin Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions
Carboplatin, Etoposide, Ifosfamide, Liposomal ARA-C, Obinutuzumab
Drug
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 31 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced May 17, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Loncastuximab, Prednisone, Rituximab, Roflumilast, Vincristine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 4, 2026, 10:19 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Interventions
Loncastuximab Tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lynwood, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 8, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Endometrial Cancer, Lymphoma, T-Cell, Mesothelioma, Malignant, Metastatic Castration-resistant Prostate Cancer, Ovarian Clear Cell Carcinoma, Prostatic Neoplasms, Castration-Resistant
Interventions
Enzalutamide, Tulmimetostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
17
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced May 15, 2026, 6:32 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Lymphoma
Interventions
Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
Drug
Lead sponsor
John Lister
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Apr 29, 2026, 9:42 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
Interventions
Not listed
Lead sponsor
OWKIN
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced May 6, 2026, 2:07 AM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 12:52 AM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Epcoritamab, External Beam Radiation Therapy, Glofitamab
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 1:22 AM EDT